The head of the Food and Drug Administration’s drug center abruptly resigned Sunday amid concerns about his personal conduct. A federal spokesperson said Dr.
The FDA has expanded the approval of Winrevair to include treatment of adults with PAH WHO Group 1 to improve exercise capacity and WHO FC, and reduce the risk of clinical worsening events including ...
Company’s first metered-dose inhalation (MDI) product and establishes a new growth vector for the Affordable Medicines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results